Compass Therapeutics, Inc. CMPX
We take great care to ensure that the data presented and summarized in this overview for Compass Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CMPX
View all-
Tang Capital Management LLC San Diego, CA16.8MShares$82 Million2.87% of portfolio
-
Orbimed Advisors LLC San Diego, CA15.2MShares$74.3 Million1.95% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.1MShares$68.8 Million1.59% of portfolio
-
Blackstone Inc New York, NY9.84MShares$48 Million0.17% of portfolio
-
Vivo Capital, LLC Palo Alto, CA9.55MShares$46.6 Million5.69% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.06MShares$34.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.61MShares$32.3 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.19MShares$25.3 Million0.03% of portfolio
-
Bio Impact Capital LLC Cambridge, MA5.08MShares$24.8 Million3.45% of portfolio
-
Bvf Inc San Francisco, CA4.75MShares$23.2 Million0.96% of portfolio
Latest Institutional Activity in CMPX
Top Purchases
Top Sells
About CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Insider Transactions at CMPX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 09
2026
|
Thomas J. Schuetz CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
46,777
-0.7%
|
$233,885
$5.35 P/Share
|
|
Jan 02
2026
|
Jonathan Anderman General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+46.73%
|
$750,000
$5.17 P/Share
|
|
Jan 02
2026
|
Neil Lerner Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+14.04%
|
$312,500
$5.17 P/Share
|
|
Jan 02
2026
|
Thomas J. Schuetz CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+3.6%
|
$1,250,000
$5.17 P/Share
|
|
Jan 02
2026
|
Barry Shin CFO |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+19.23%
|
$625,000
$5.17 P/Share
|
|
Nov 16
2025
|
Thomas J. Schuetz CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
44,025
-0.68%
|
$176,100
$4.83 P/Share
|
|
May 27
2025
|
Thomas J. Schuetz CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
10,000
+0.15%
|
$20,000
$2.11 P/Share
|
|
Apr 09
2025
|
Carl L Gordon Director |
SELL
Open market or private sale
|
Indirect |
3,571,428
-100.0%
|
$3,571,428
$1.59 P/Share
|
|
Apr 09
2025
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
3,571,428
-100.0%
|
$3,571,428
$1.59 P/Share
|
|
Apr 07
2025
|
Jonathan Anderman General Counsel |
BUY
Open market or private purchase
|
Direct |
20,000
+48.78%
|
$20,000
$1.54 P/Share
|
|
Apr 07
2025
|
Neil Lerner Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+5.88%
|
$20,000
$1.42 P/Share
|
|
Feb 08
2025
|
Thomas J. Schuetz CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
41,687
-0.64%
|
$125,061
$3.5 P/Share
|
|
Jan 09
2025
|
Thomas J. Schuetz CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
58,054
-0.88%
|
$58,054
$1.86 P/Share
|
|
Dec 09
2024
|
Barry Shin CFO |
BUY
Grant, award, or other acquisition
|
Direct |
400,000
+50.0%
|
$400,000
$1.65 P/Share
|
|
Feb 08
2024
|
Vered Bisker Leib CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
49,198
-1.55%
|
$49,198
$1.45 P/Share
|
|
Feb 08
2024
|
Thomas J. Schuetz CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
44,782
-0.68%
|
$44,782
$1.45 P/Share
|
|
Jan 09
2024
|
Thomas J. Schuetz CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
637,500
+8.79%
|
$637,500
$1.93 P/Share
|
|
Jan 09
2024
|
Vered Bisker Leib CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,753,125
+35.58%
|
$1,753,125
$1.93 P/Share
|
|
Nov 17
2023
|
Vered Bisker Leib CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
64,415
-4.34%
|
$64,415
$1.5 P/Share
|
|
Nov 17
2023
|
Thomas J. Schuetz CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
44,025
-0.73%
|
$44,025
$1.5 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 588K shares |
|---|---|
| Open market or private purchase | 50K shares |
| Open market or private sale | 7.14M shares |
|---|---|
| Payment of exercise price or tax liability | 132K shares |